Capricor Therapeutics Inc (CAPR)

[Volcano]

The Japanese pharma is no stranger to the rare muscle degeneration disease having gained FDA approval for Viltepso in August 2020, setting it up to compete with Sarepta's Vyondys 53 in the same patient population.

That market experience alongside a rare disease focus and appetite for new pipeline assets were three key attributes Capricor looked for when shopping around for partners, Marbán said.